Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SGTX Sigilon Therapeutics (SGTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Sigilon Therapeutics Stock (NASDAQ:SGTX) 30 days 90 days 365 days Advanced Chart Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Sigilon Therapeutics alerts:Sign Up Key Stats Today's Range$22.09▼$23.1050-Day Range$20.92▼$23.0652-Week Range$3.77▼$28.00Volume83,600 shsAverage Volume62,902 shsMarket Capitalization$56.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SGTX Stock News HeadlinesLilly & Co Eli's Net WorthMay 1, 2024 | benzinga.comMCRB Seres Therapeutics, Inc.April 14, 2024 | seekingalpha.comI've got news for you… Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekNovember 21, 2024 | DTI (Ad)Beam Therapeutics Inc.October 22, 2023 | wsj.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | markets.businessinsider.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.August 1, 2023 | finance.yahoo.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 31, 2023 | msn.comSee More Headlines SGTX Stock Analysis - Frequently Asked Questions How were Sigilon Therapeutics' earnings last quarter? Sigilon Therapeutics, Inc. (NASDAQ:SGTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($8.19) EPS for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The company had revenue of $1.95 million for the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%. When did Sigilon Therapeutics' stock split? Sigilon Therapeutics shares reverse split on the morning of Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Sigilon Therapeutics IPO? Sigilon Therapeutics (SGTX) raised $101 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO. What other stocks do shareholders of Sigilon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sigilon Therapeutics investors own include Tesla (TSLA), NIO (NIO), Athenex (ATNX), Palantir Technologies (PLTR), Plug Power (PLUG), CrowdStrike (CRWD) and Li Auto (LI). Company Calendar Last Earnings11/10/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SGTX CUSIPN/A CIK1821323 Websigilon.com Phone617-336-7540FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.2328) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net Margins-171.29% Pretax Margin-171.29% Return on Equity-83.07% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$12.94 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$15.68 per share Price / Book1.43Miscellaneous Outstanding Shares2,510,000Free Float2,351,000Market Cap$56.40 million OptionableNot Optionable Beta4.12 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:SGTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigilon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.